NTRK
MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib
The research will include preclinical and clinical studies of ROS1/NTRK inhibitor repotrectinib and MET inhibitor elzovantinib in several tumor types.
Illumina Adds CDx Indication to European TruSight Oncology Test for NTRK Gene Fusion Detection
The CDx pan-cancer indication will allow the identification of patients with NTRK gene fusions who may benefit from therapy with Bayer's Vitrakvi (larotrectinib).
Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial
Pyramid will use Tempus'Â TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200.
The analysis of three clinical trials also suggested that NTRK fusion-positive colorectal cancers don't respond as well as other tumors to Rozlytrek.
Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients
Premium
The project is focused on building a workflow to improve guideline-concordant molecular testing, which researchers hope will reduce insurance denials and improve community access.